Wealthfront Advisers LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 176,885 shares of the company’s stock after selling 70,240 shares during the quarter. Wealthfront Advisers LLC’s holdings in Johnson & Johnson were worth $27,417,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in the company. DORCHESTER WEALTH MANAGEMENT Co increased its stake in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P grew its position in Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares in the last quarter. AMI Investment Management Inc. grew its position in Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after acquiring an additional 1,475 shares in the last quarter. Equitable Holdings Inc. grew its position in Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after acquiring an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd grew its position in Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after acquiring an additional 20,528 shares in the last quarter. Institutional investors and hedge funds own 67.57% of the company’s stock.
Analyst Ratings Changes
Several analysts have commented on JNJ shares. Stifel Nicolaus boosted their target price on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Atlantic Securities decreased their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Barclays upped their price objective on shares of Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a report on Monday. StockNews.com assumed coverage on shares of Johnson & Johnson in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a report on Friday, July 21st. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $171.60.
Johnson & Johnson Trading Up 0.2 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.59 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 10.76 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 2.76%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Insider Activity
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Markets Are Loving Boeing Stock After Earnings, Time To Buy?
- What Are Dividend Champions? How to Invest in the Champions
- Nothing But Upside For High-Yield Verizon?
- Consumer Discretionary Stocks Explained
- Will Coca-Cola Stock Move To New Highs Or Fall Flat In 2023?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
